Opal Therapeutics specializes in research and development services focused on reproductive and gynecological disorders, utilizing advanced in vitro models to study female biology. The company addresses the significant underfunding and lack of therapeutic options for women's health issues, aiming to enhance the quality of life for affected individuals.
Funding
Funding not disclosed
Founders
Product
Problem
Drug development for reproductive and gynecological disorders is significantly underfunded, resulting in limited therapeutic options for women's health issues. Traditional rodent models often fail to accurately replicate key features of the female reproductive system, leading to unreliable preclinical data.
Solution
Opal Therapeutics offers R&D services and therapeutic development for women’s health, utilizing patient-derived uterine organoids to create lab-grown uterine models. These models, including endometrial and myometrial organoids, provide a more accurate, scalable, and clinically relevant platform for developing and testing treatments for conditions like fibroids, endometriosis, and other gynecological disorders. By mimicking the structure and biology of real human tissue, Opal Therapeutics aims to transform how we study and treat these conditions.
Target Audience
The primary customers are researchers and pharmaceutical companies focused on developing treatments for reproductive and gynecological disorders.
Features
- Patient-derived uterine organoids that mimic the structure and biology of real human tissue
- Endometrial and myometrial organoid models
- Scalable and clinically relevant platform for drug development
- Advanced in vitro models for studying female biology